Posters

    Xenobiotic metabolism response to 3R4F or THS2.2 exposure: from pre-clinical to clinical

    Pouly, S.; Talikka, M.; van der Plas, A.; Titz, B.; Iskandar, A.; de La Bourdonnaye, G.; Blanc, N.; Martin, F.; Haziza, C.; Ivanov, N. V.; Lüdicke, F.; Hoeng, J.; Peitsch, M. C.

    Conference date
    Mar 12, 2019
    Conference name

    Society of Toxicology (SOT) 2019
    Link to more information
    Topic
    Summary

    Cytochrome P450s (CYP) are prominent xenobiotic metabolism enzymes that detoxify or activate xenobiotic compounds. CYP1A2 is a key factor in the activation metabolism of various constituents found in cigarette smoke (CS), in particular of polycyclic aromatic hydrocarbons, and is indicative of CS exposure. The Tobacco Heating System (THS) 2.2 is designed to heat tobacco instead of burning it, thereby significantly reducing the levels of harmful chemicals in the aerosol compared with those found in cigarette smoke. As part of the pre-clinical THS 2.2 assessment, mRNA and protein abundance of CYP1A2 was measured in the livers of ApoE-/- mice exposed to CS from a 3R4F reference cigarette, aerosol from THS 2.2, or fresh air (sham). Elevated levels of CYP1A2 were observed in the livers of mice in the 3R4F group, but not in the THS 2.2 group, compared with the sham group. The combined enzymatic activity of CYP1A1 and CYP1B1 was further shown to be lower in human organotypic bronchial and nasal cultures exposed to THS 2.2 aerosol than in those exposed to 3R4F CS. Overall, gene expression levels of xenobiotic metabolizing enzymes and transporters were less impacted by exposure to THS 2.2 aerosol than exposure to 3R4F CS in all pre-clinical models tested. In addition, a causal biological network model that captures the xenobiotic metabolism response in the respiratory tract demonstrated weaker perturbation upon THS 2.2 aerosol compared with CS exposure at nicotine-matched exposure concentrations. Finally, in four clinical studies conducted with THS 2.2, CYP1A2 activity was found to be lower in the plasma of subjects who abstained from smoking or switched to THS 2.2 for five days compared with subjects who continued smoking. Taken together, these results demonstrate an overall reduced impact on xenobiotic metabolism for exposure to THS 2.2 compared with cigarette in non-clinical in vitro and in vivo models as well as clinical studies.

    Related Publications

    Verification Of Systems Biology Research In The Age Of Collaborative- Competition

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative- Competition: Biological Network Models

    Systems Toxicology

    Verification of systems biology research in the age of collaborative competition

    Systems Toxicology

    An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models

    Systems Toxicology

    Community-Reviewed Biological Network Models for Toxicology and Drug Discovery Applications

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative - Competition

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative- Competition

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative- Competition: Biological Network Models

    Systems Toxicology

    Verification of systems biology research in the age of collaborative competition

    Systems Toxicology

    An In Vitro Systems Toxicology Assessment of Novel Electronic Vapor Device by Using Air–Liquid Interface Buccal, Bronchial, Small Airway, and Alveolar Culture Models

    Systems Toxicology

    Community-Reviewed Biological Network Models for Toxicology and Drug Discovery Applications

    Systems Toxicology

    Verification Of Systems Biology Research In The Age Of Collaborative - Competition

    Systems Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.